Perseris Now Available for the Treatment of Schizophrenia in Adults
Prior to starting Perseris, tolerability with oral risperidone should be established.
Perseris (risperidone; Indivior), a once-monthly subcutaneous (SC) risperidone-containing, long-acting injectable, is now available for the treatment of schizophrenia.
Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month. Data showed clinically relevant levels of risperidone were achieved after the first injection without a loading dose or any supplemental oral risperidone doses.
Prior to starting Perseris, tolerability with oral risperidone should be established. Based on average plasma concentrations of risperidone and total active moiety, Perseris 90mg corresponds to 3mg/day oral risperidone and Perseris 120mg corresponds to 4mg/day oral risperidone.
Perseris is available in strengths of 90mg and 120mg and is supplied in single-dose kits containing the risperidone powder, delivery system, and safety needle. Each injection must be administered by a healthcare professional using the prepackaged injection syringe and enclosed safety needle. Prior to use, the product is constituted by coupling the liquid and powder syringes and passing the contents back and forth between the syringes; failure to fully mix the medication could result in incorrect dosage.
For more information visit Perseris.com.